0

Controlled Trial of Hartmann's Solution Versus 0.9% Saline for Diabetic Ketoacidosis

Michael Yung, Georgia Letton, Steve Keeley

J Paediatr Child Health. 2017 Jan;53(1):12-17.

PMID: 28070957

Abstract:

Aim:
We aimed to determine whether using a balanced salt solution, Hartmann's solution (HS), in diabetic ketoacidosis (DKA) shortens the time to normalise acid-base status through the avoidance of hyperchloremic metabolic acidosis compared with 0.9% normal saline (NS).
Methods:
We conducted a double-blind, randomised controlled trial comparing HS to NS as the initial intravenous fluid in children with DKA. Patients were stratified by severity (pH < 7.1) and known or new diabetes. Electrolytes, venous blood gases and glucose were measured every 2 h until intravenous fluids were ceased. The primary outcome was the time for the plasma bicarbonate to reach 15 mmol/L. Secondary outcomes included time to normalise pH (7.3), time to receive subcutaneous (SC) insulin, change in sodium and insulin requirement.
Results:
A total of 77 children were enrolled. The groups were similar at baseline. There was no difference in the time to reach a bicarbonate of 15 mmol/L: geometric mean (SD) 8.6 (2.3) h for NS versus 6.2 (4.7) h for HS, ratio 1.4 (95% confidence interval 0.8-2.5), and no difference in time to normalise pH: NS 8.5 (2.3) h versus HS group 7.5 (1.8) h, ratio 1.1 (0.8-1.6). Kaplan-Meier survival estimates showed shorter times for these end-points in the severe subgroup: log-rank test P = 0.0277 and 0.0024, respectively. There was no difference in time to SC insulin, NS: 15.2 (2.4) h versus HS 14.3 (1.6) h, ratio 1.1 (0.8-1.5). Patients treated with HS received significantly less total fluids/kg.
Conclusions:
HS is an acceptable alternative to NS in DKA and may benefit those with severe DKA.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
IAR42410409 Sodium taurodeoxycholate-2,2,3,3,11,11-d6 solution Sodium taurodeoxycholate-2,2,3,3,11,11-d6 solution Price
qrcode